|
|
|
|
||
Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of DirectorsI’m a BSGM shareholder whose an electrical engineer who Rob Cos asked to visit the LA HQ and their engineering executives and evaluate the PURE EP system. My summary of that trip is on the BioSig Tech. (BSGM) & Electrophysiology Sector semi-private board at this link if anyone is interested: https://www.investorvillage.com/groups.asp?mb=19723&mn=64&pt=msg&mid=19371777 Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors May 21, 2019 Santa Monica, CA, May 21, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that Dr. Jerome B. Zeldis agreed to re-join the Company as an Independent Director, effective immediately. Jerome (“Jerry”) Zeldis, M.D., Ph.D brings extensive life sciences experience gained primarily through his career at Celgene, Inc. He previously served as Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation (NASDAQ:CELG), a publicly traded, fully integrated biopharmaceutical company, where he was employed for nearly 20 years, starting in 1997. Celgene Corporation’s Board of Directors and shareholders recently approved an offer to be acquired by Bristol Myers-Squibb (NYSE:BMY) in a cash and stock deal valued at $74 billion at the time of the offer. “I am very pleased with the progress that has occurred from the time I left the Board until now,” commented Dr. Zeldis. “I look forward to the realization of the clinical benefit that may occur by reducing noise in a variety of settings in which detection of small signals is critical for therapeutic interventions.” Since 2016, Dr. Zeldis serves as Chief Medical Officer and President of Clinical Research, Medical Affairs Drug Safety, Quality, and Regulatory at Sorrento Therapeutics, Inc. He attended Brown University for an AB, MS, followed by Yale University for a MPhil, MD, PhD in Molecular Biophysics and Biochemistry. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Dr. Zeldis is a named inventor on 43 US patents, has published 122 peer reviewed articles and 24 reviews, book chapters and editorials. “Dr. Zeldis is one of our earliest investors and has watched our company grow from the beginning. He continues to invest in the Company. We are eager to work with him to capitalize on his extensive experience in clinical development, regulatory strategy, shareholder wealth creation, and platform development. We are especially excited regarding Jerry’s understanding of bioelectronic medicine and how our PURE EP™ System can contribute to this rapidly emerging field,” stated Kenneth L. Londoner, Founder, Chairman and CEO of BioSig Technologies, Inc. BioSig recently exhibited at the Heart Rhythm Society’s 40th Annual Scientific Sessions on May 8-11, 2019 at Moscone Center in San Francisco, CA. Previously, BioSig announced that it successfully conducted first patient cases using its PURE EP™ System at the Texas Cardiac Arrhythmia Institute in Austin, TX, Greenville Memorial Hospital in Greenville, SC and Indiana University School of Medicine. These initial experiences suggested improved cardiac signal detection and fidelity. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
225128 | Re: Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors | cm4cmc | 2 | 5/20/2019 4:53:39 PM |